Research
Hormonal
Resmetirom, a THR-β agonist, improves histologic features of MASLD, including resolution of steatohepatitis without worsening fibrosis and improvement in fibrosis stage, in patients with F1-F3 fibrosis.
Resmetirom is the first FDA-approved drug for MASH. In clinical trials, doses of 80mg or 100mg taken daily for 52 weeks significantly improved liver inflammation and fibrosis compared to placebo. It is an option for those with F1-F3 fibrosis.
StrongSupportsHIGH confidence
resmetirom demonstrated superiority at 52 weeks in the primary endpoints of resolution of MASH without worsening of fibrosis (26% and 30% for resmetirom versus 10% in placebo group) and improvement in fibrosis of at least one stage without NAS worsening (24% and 26% for resmetirom versus 14% for placebo).
Why this rating
Based on a specific randomized placebo-controlled trial (MAESTRO-NASH) cited in the review.
Source
At the Crossroads of Health and Disease: Consequences of Fat in the Liver
Matthew Dukewich et al. · Annual Review of Physiology · 2025
DOI 10.1146/annurev-physiol-022724-105515
narrative_reviewCited 11×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weight loss of at least 10% of total body weight reverses steatohepatitis and improves histologic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).Good
- Vitamin E supplementation (800 IU daily) improves steatohepatitis, hepatic steatosis, and inflammation in adults with MASH who do not have diabetes, but does not improve fibrosis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →